Engineered immune cells take on tough leukemia

NCT ID NCT04150497

Recruiting now Disease control Sponsor: Cellectis S.A. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new treatment called UCART22 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. UCART22 uses donor immune cells that are engineered in a lab to recognize and attack cancer cells. The trial will enroll about 52 participants to evaluate the safety of the therapy and see if it can shrink tumors. It is an early-stage study, so the main goals are to find the right dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

UCART22 (allogeneic engineered T-cells targeting CD22) and alemtuzumab (CLLS52) for lymphodepletion

What this could lead to

If successful, this could provide a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia who have run out of standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with only 52 participants. The therapy may cause serious side effects, and it is not yet known if it will effectively control the disease long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Rennes - Hopital Pontchaillou
RECRUITING

Rennes, 35033, France
CHU de Nantes - Hôtel-Dieu
RECRUITING

Nantes, 44093, France
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Hôpital Lyon Sud
RECRUITING

Pierre-Bénite, 69310, France
Hôpital Robert Debré - Service d'hémato-immunologie
RECRUITING

Paris, 75019, France
Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie
RECRUITING

Paris, 75010, France
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States
Sarah Cannon - Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon - HCA Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon - St. David's South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
Sarah Cannon - Texas Transplant Institute at Methodist Hospital
RECRUITING

San Antonio, Texas, 78229, United States
University of California, Los Angeles (UCLA) - Medical Center
RECRUITING

Los Angeles, California, 90095, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60647, United States
University of Colorado - Aurora Cancer Center
RECRUITING

Aurora, Colorado, 80045, United States
University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States
Weill Medical College of Cornell University
WITHDRAWN

New York, New York, 10065, United States